Name | Number of supported studies | Average coverage | |
---|---|---|---|
lung | 15 studies | 28% ± 13% | |
intestine | 7 studies | 36% ± 15% | |
uterus | 6 studies | 44% ± 16% | |
kidney | 5 studies | 31% ± 12% | |
placenta | 4 studies | 30% ± 8% | |
prostate | 4 studies | 25% ± 8% | |
breast | 4 studies | 43% ± 10% | |
adrenal gland | 3 studies | 24% ± 7% | |
esophagus | 3 studies | 38% ± 14% | |
lymph node | 3 studies | 28% ± 7% | |
skin | 3 studies | 34% ± 14% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
lung | 94% | 9795.39 | 545 / 578 | 88% | 47.30 | 1018 / 1155 |
bladder | 81% | 6015.81 | 17 / 21 | 84% | 57.54 | 424 / 504 |
prostate | 78% | 5238.46 | 190 / 245 | 87% | 103.80 | 435 / 502 |
uterus | 72% | 3486.90 | 122 / 170 | 91% | 73.30 | 417 / 459 |
kidney | 81% | 6858.39 | 72 / 89 | 77% | 57.52 | 696 / 901 |
breast | 82% | 8939.39 | 377 / 459 | 75% | 38.67 | 842 / 1118 |
thymus | 75% | 5578.40 | 489 / 653 | 78% | 113.06 | 469 / 605 |
stomach | 64% | 6674.02 | 231 / 359 | 86% | 34.90 | 247 / 286 |
intestine | 62% | 4332.67 | 596 / 966 | 89% | 41.52 | 467 / 527 |
liver | 73% | 5172.40 | 164 / 226 | 74% | 24.51 | 299 / 406 |
pancreas | 52% | 1857.22 | 172 / 328 | 91% | 45.73 | 162 / 178 |
ovary | 64% | 3058.76 | 115 / 180 | 78% | 38.22 | 336 / 430 |
esophagus | 46% | 2897.40 | 667 / 1445 | 83% | 45.47 | 151 / 183 |
skin | 68% | 6687.98 | 1230 / 1809 | 40% | 10.57 | 187 / 472 |
adipose | 95% | 10266.20 | 1140 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 92% | 7548.86 | 1228 / 1335 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 87% | 63.94 | 39 / 45 |
adrenal gland | 36% | 1866.12 | 93 / 258 | 49% | 24.65 | 113 / 230 |
brain | 24% | 929.84 | 629 / 2642 | 56% | 22.26 | 398 / 705 |
heart | 71% | 5400.91 | 613 / 861 | 0% | 0 | 0 / 0 |
peripheral blood | 41% | 1154.92 | 378 / 929 | 0% | 0 | 0 / 0 |
muscle | 33% | 919.43 | 261 / 803 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 28% | 6.87 | 8 / 29 |
spleen | 18% | 552.61 | 43 / 241 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 14% | 2.02 | 11 / 80 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0034976 | Biological process | response to endoplasmic reticulum stress |
GO_0006357 | Biological process | regulation of transcription by RNA polymerase II |
GO_0010628 | Biological process | positive regulation of gene expression |
GO_0070373 | Biological process | negative regulation of ERK1 and ERK2 cascade |
GO_0000122 | Biological process | negative regulation of transcription by RNA polymerase II |
GO_0030968 | Biological process | endoplasmic reticulum unfolded protein response |
GO_0006094 | Biological process | gluconeogenesis |
GO_0034198 | Biological process | cellular response to amino acid starvation |
GO_1903984 | Biological process | positive regulation of TRAIL-activated apoptotic signaling pathway |
GO_0008284 | Biological process | positive regulation of cell population proliferation |
GO_0035914 | Biological process | skeletal muscle cell differentiation |
GO_0045944 | Biological process | positive regulation of transcription by RNA polymerase II |
GO_0005730 | Cellular component | nucleolus |
GO_0005654 | Cellular component | nucleoplasm |
GO_0090575 | Cellular component | RNA polymerase II transcription regulator complex |
GO_1990622 | Cellular component | CHOP-ATF3 complex |
GO_0000785 | Cellular component | chromatin |
GO_0005634 | Cellular component | nucleus |
GO_0042803 | Molecular function | protein homodimerization activity |
GO_0000978 | Molecular function | RNA polymerase II cis-regulatory region sequence-specific DNA binding |
GO_0001228 | Molecular function | DNA-binding transcription activator activity, RNA polymerase II-specific |
GO_0000977 | Molecular function | RNA polymerase II transcription regulatory region sequence-specific DNA binding |
GO_0001227 | Molecular function | DNA-binding transcription repressor activity, RNA polymerase II-specific |
GO_0000981 | Molecular function | DNA-binding transcription factor activity, RNA polymerase II-specific |
GO_0000976 | Molecular function | transcription cis-regulatory region binding |
GO_1990837 | Molecular function | sequence-specific double-stranded DNA binding |
GO_0042802 | Molecular function | identical protein binding |
GO_0003700 | Molecular function | DNA-binding transcription factor activity |
GO_0046982 | Molecular function | protein heterodimerization activity |
GO_0005515 | Molecular function | protein binding |
Gene name | ATF3 |
Protein name | Cyclic AMP-dependent transcription factor ATF-3 (cAMP-dependent transcription factor ATF-3) (Activating transcription factor 3) Activating transcription factor 3 Activating transcription factor 3 delta Zip3 (cDNA FLJ57271, highly similar to Cyclic AMP-dependent transcription factorATF-3) |
Synonyms | |
Description | FUNCTION: This protein binds the cAMP response element (CRE) (consensus: 5'-GTGACGT[AC][AG]-3'), a sequence present in many viral and cellular promoters. Represses transcription from promoters with ATF sites. It may repress transcription by stabilizing the binding of inhibitory cofactors at the promoter. .; FUNCTION: [Isoform 2]: Activates transcription presumably by sequestering inhibitory cofactors away from the promoters. .; FUNCTION: [Isoform 3]: Stress-induced isoform, counteracts the transcriptional repression of isoform 1. . |
Accessions | P18847 ENST00000366987.6 [P18847-1] ENST00000336937.8 [P18847-4] ENST00000366981.8 ENST00000613104.1 [P18847-5] ENST00000366983.5 [P18847-3] ENST00000341491.9 [P18847-1] Q5VTZ4 Q7Z567 A0A0A0MRJ2 ENST00000366985.5 ENST00000464547.5 [P18847-3] |